Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market

How big is Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market size?

USD 789.4 million in 2026 and USD 1,736.1 million by 2036 at an 8.2% CAGR.

Demand for subcutaneous lunsumio VELO polivy relapsed refractory LBCL is projected to expand at 8.2% CAGR between 2026 and 2036, increasing valuation from USD 789.4 million in 2026 to USD 1736.1 million by 2036. Access to convenient therapy is essential for patients battling difficult blood cancers. Relapsed or refractory LBCL treatment programs assess fixed-duration combinations offering dependable response evidence and outpatient delivery potential. A major health report highlights the urgent clinical need for these accessible treatment pathways. In February 2025, the National Cancer Institute reported an estimated 80,620 new United States non-Hodgkin lymphoma cases during 2024. This high disease burden reinforces why oncologists prioritize flexible treatment schedules that reduce hospital visits for their patients.

Global oncology networks adopt tailored strategies on evaluating subcutaneous lymphoma regimens. United States and German care networks prioritize response durability and structured toxicity-management records during therapy reviews. Japanese and South Korean centers emphasize subcutaneous treatment experience and dependable specialist access. Prominent international clinical trials directly support such careful hospital evaluations.The SUNMO study enrolled 208 participants as confirmed in the primary analysis data cutoff of February 2025. Participating centers provide valuable clinical experience across different treatment environments and patient referral structures. Such widespread research ultimately helps medical teams deliver safe and effective therapies to diverse patient populations.

Key Takeaways of the Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market

• Subcutaneous Lunsumio + Polivy (VELO) is estimated to capture 41.4% of therapy regimen demand in 2026, supported by fixed-duration combination design and outpatient delivery potential, with Budde and colleagues reporting a 59.2% objective response rate during dose-expansion assessment of mosunetuzumab with polatuzumab vedotin.
• Second-line therapy is anticipated to hold 45.7% of line-of-therapy demand in 2026, reflecting treatment urgency following frontline failure among patients with limited suitability for intensive salvage procedures.
• Hospitals are projected to account for 41.3% of end-user demand in 2026, guided by multidisciplinary hematology services and immediate clinical support requirements during initial treatment cycles.
• Subcutaneous administration is forecast to secure 67.5% of route-of-administration demand in 2026, with Roche reporting an approximate injection duration of one minute, supporting shorter chair time and predictable outpatient scheduling.
• Germany leads country growth at an 8.8% CAGR through 2036, followed by Japan at 8.0% CAGR driven by ageing-related lymphoma care requirements.
• Roche and Genentech anchor development through Lunsumio VELO and Polivy, while AbbVie, Genmab, and Bristol Myers Squibb compete through subcutaneous epcoritamab and cellular therapy options.

Analyst Perspective

"The subcutaneous Lunsumio VELO Polivy relapsed refractory LBCL market will be shaped by the balance between treatment convenience and reliable disease control. Clinical adoption will depend on response durability, safety evidence, and the feasibility of delivering therapy through outpatient pathways. Companies that strengthen specialist education, treatment protocols, and regional access will be better positioned to support broader clinical use."

—  Anurag Sharma, Principal Analyst at Future Market Insights

Source: Internal market analysis, 2026.

How is Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market segmented?

The subcutaneous lunsumio VELO polivy relapsed refractory LBCL industry is segmented by therapy regimen, line of therapy, end user, route of administration, and region.

The subcutaneous lunsumio VELO polivy relapsed refractory LBCL sector is segmented by therapy regimen, line of therapy, end user, route of administration, and region. Therapy regimen coverage includes subcutaneous lunsumio + polivy (VELO) and lunsumio monotherapy followed by polivy combination therapy and other bispecific antibody combinations. Line of therapy coverage addresses second-line and third-line followed by fourth-line and later treatment. End user coverage encompasses hospitals and cancer centers supported by specialty oncology clinics and academic and research institutes. Route of administration coverage includes subcutaneous and intravenous treatment delivery. Regional coverage includes North America and Latin America together with Western Europe and Eastern Europe. East Asia and South Asia and Pacific extend geographic analysis across established and developing oncology systems. Middle East and Africa complete regional assessment across emerging hematology services.

Why does Subcutaneous Lunsumio + Polivy (VELO) shape therapy regimen selection?

Budde and colleagues reported in January 2024 an objective response rate of 59.2% during dose-expansion assessment of mosunetuzumab with polatuzumab vedotin. Clinical performance supports review of combined immune engagement and targeted cytotoxic delivery across transplant-ineligible relapsed or refractory LBCL pathways. Predictable cycle planning reduces scheduling pressure across outpatient hematology units during fixed-duration care. Clear escalation pathways help smaller centers participate without weakening early safety oversight.

• Subcutaneous Lunsumio + Polivy (VELO) is set to represent 41.4% share of therapy regimen in 2026, backed by fixed-duration treatment design and outpatient delivery potential. Hematology teams assess response durability and early-cycle safety support across complete treatment pathways prior to routine use.
• Lunsumio monotherapy and polivy combination therapy address patients requiring alternative treatment intensity or sequencing approaches. Other bispecific antibody combinations extend review across patient groups with different prior therapies and clinical profiles.

How does Second-Line therapy shape line-of-therapy demand?

Clinical results direct specialist attention toward timely second-line treatment for transplant-ineligible patients following frontline disease progression. Budde and colleagues reported median progression-free survival of 11.5 months for subcutaneous mosunetuzumab combined with polatuzumab vedotin in the SUNMO phase III trial for subcutaneous mosunetuzumab combined with polatuzumab vedotin during SUNMO assessment. Earlier intervention may preserve patient fitness and reduce exposure to repeated salvage regimens. Referral teams also need prompt eligibility review to limit treatment delays following confirmed progression.

• Second-line therapy is anticipated to secure 45.7% share in 2026, reflecting treatment urgency following initial regimen failure and limited suitability for intensive procedures. Hematologists compare disease tempo and prior treatment exposure with patient fitness across second-line decision pathways.
• Third-line and fourth-line or later treatment retain importance for heavily treated patients requiring alternative mechanisms. Clinical selection considers previous chimeric antigen receptor T-cell therapy exposure and eligibility for next generation immunotherapies across specialist centers.

Why do hospitals lead end-user demand?

Chavez and colleagues reported in June 2026 a randomized study population of 80 patients receiving subcutaneous mosunetuzumab-based combination treatment or comparator therapy. Trial design illustrates hospital involvement in treatment administration and safety observation across relapsed or refractory LBCL care. Centralized laboratory review supports dose decisions and early infection management throughout each cycle. Formal handoffs between inpatient and outpatient teams preserve continuity during symptom escalation.

• By end-user, hospitals are projected to garner 41.3% share in 2026 since it is guided by multidisciplinary hematology services and immediate clinical support during initial treatment cycles. Pharmacy and nursing teams coordinate dosing preparation and laboratory review with toxicity escalation across scheduled patient visits.
• Cancer centers and specialty oncology clinics extend access through referral relationships and protocol-led treatment delivery. Academic and research institutes promote evidence development and specialist training across advanced blood cancer treatment programs.

How does subcutaneous administration retain route leadership?

Short delivery supports outpatient scheduling and reduces infusion-chair use across participating hematology services. Roche reported in September 2025 an approximate injection duration of 1 minute for subcutaneous Lunsumio administration. Brief visits improve chair turnover and create predictable appointment blocks for repeat dosing. Nursing preparation supports consistent symptom documentation throughout early observation periods.

• In 2026, subcutaneous administration is forecast to hold 67.5% share in 2026 as it reflects treatment convenience and reduced administration time across repeated clinical visits. Hospital teams assess formulation handling and injection-site monitoring with step-up dosing requirements during initial cycles.
• Intravenous administration retains utility through established infusion protocols and extensive clinical familiarity across lymphoma services. Route selection considers patient preference and observation capacity together with experience in subcutaneous drug delivery.

What are drivers, restraints, and opportunities in Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market?

Fixed-duration treatment evidence and outpatient administration support combination review across eligible LBCL patients. Toxicity-management needs and uneven community hematology capacity may delay routine use across smaller treatment centers.

• Driver: Hematology teams need effective second-line treatment for transplant-ineligible patients experiencing disease progression following frontline therapy. Fixed-duration combination design supports treatment planning without requiring extended inpatient or cellular-therapy coordination.
• Restraint: Step-up dosing and cytokine release syndrome surveillance create additional clinical responsibilities during initial treatment cycles. Smaller oncology centers may require specialist partnerships and formal escalation procedures prior to adoption.
• Opportunity: Community-ready education and shorter administration may extend advanced lymphoma treatment beyond major academic hospitals. Defined referral arrangements and responsive clinical support may improve regional access for suitable patients.

Clinical efficacy supports demand for combination treatment across relapsed or refractory LBCL pathways. Genentech reported in December 2025 for median progression-free survival of 25.4 months in the Phase Ib/II GO40516 study of subcutaneous Lunsumio combined with Polivy in relapsed or refractory LBCL. Longer disease control strengthens hospital interest in fixed-duration regimens supported by complete response and safety evidence. Extended control periods reduce repeated salvage planning and preserve outpatient capacity for other hematology services. Predictable treatment completion also supports clearer discussions with patients and caregivers.

Safety responsibilities restrain immediate adoption across treatment centers lacking established bispecific-antibody experience. Genentech reported in December 2025 about cytokine release syndrome in approximately one in four participants in the SUNMO study evaluating subcutaneous Lunsumio VELO combined with Polivy in relapsed or refractory LBCL, with less than 5% of patients experiencing Grade 2 or 3 events. Structured cytokine release syndrome management remains necessary during step-up dosing and early treatment observation. Early implementation requires scheduled observation windows and prompt access to experienced clinicians. Centers lacking such arrangements often delay use until referral agreements are established.

Community treatment creates an opportunity for suitable patients living outside major academic centers. Genmab reported in September 2025 stating for outpatient administration of the first full epcoritamab dose in 92.0% of participants who received the first full dose. Experience from comparable targeted oncology biologics supports development of community-ready education and escalation pathways. Regional programs benefit from shared protocols covering dosing and emergency transfer. Consistent education helps community teams identify suitable patients and coordinate specialist review.

How are country CAGRs aligned in Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market?

Country	CAGR
Germany	8.8%
Japan	8.0%
United Kingdom	7.7%
South Korea	6.7%
United States	6.4%

Source: Country forecast analysis, 2026.

How do country-level CAGRs compare in Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market?

Country comparison shows a gradual step-down across profiled healthcare systems. Germany occupies the upper position followed by Japan and the United Kingdom. South Korea and the United States complete the disclosed country set. The 2.4-percentage-point spread shows the profiled countries sharing a steady expansion outlook, although their relative positions indicate different levels of treatment adoption.

• Germany leads the comparison and establishes Western Europe as an important adoption center among profiled countries.
• Japan follows Germany and maintains a limited rate difference from the leading position.
• United Kingdom occupies the central position through established cancer referral and treatment pathways.
• South Korea follows through tertiary-hospital capacity and prompt clinical technology assessment.
• United States completes the comparison despite extensive bispecific-antibody and cellular-therapy experience.

Countries recording similar CAGRs may present different treatment-entry conditions through clinical capacity and payer review. Full report analysis covers North America and Latin America together with Western Europe and Eastern Europe. East Asia and South Asia and Pacific receive separate assessment across national treatment systems. Middle East and Africa complete geographic coverage.

Country-wise Analysis

• Subcutaneous Lunsumio VELO Polivy relapsed refractory LBCL sales in Germany are forecast to expand at 8.8% CAGR between 2026 and 2036, driven by hospital capacity and established hematology services. Eurostat reported in July 2026 noting Germany maintained 759 hospital beds per 100,000 people during 2024, offering institutional capacity for complex lymphoma treatment. Extensive inpatient resources support early-cycle observation followed by planned outpatient administration. Regional referral links allow university hospitals to transfer routine follow-up closer to patient homes. Standardized documentation supports consistent treatment decisions across participating centers.
• Statistics Bureau of Japan reported in April 2025 for residents aged 65 years or older represented 29.3% of Japan’s population during 2024, increasing attention toward accessible lymphoma treatment. Ageing-related care requirements encourage fixed-duration regimens supported by structured toxicity monitoring. Demand across Japan is projected to rise at 8.0% CAGR from 2026 to 2036, aided by specialist concentration and subcutaneous treatment experience. Coordinated pharmacy services help specialists manage step-up dosing without extending routine clinic visits. Local evidence generation also supports careful adoption among hospitals serving older populations.
• Centralized cancer services and regional referral networks support treatment assessment across the United Kingdom. Industry in the United Kingdom is estimated to scale at 7.7% CAGR during the study period, reflecting demand for outpatient regimens and efficient capacity use. NHS England reported in March 2026 for 4,899 urgent suspected cancer referrals per 100,000 registered people during 2024-2025, indicating sustained pressure across oncology pathways. Capacity pressures favor regimens offering defined treatment duration and manageable outpatient observation. Regional hematology networks distribute follow-up responsibilities across specialist and local services.
• Ministry of Data and Statistics reported in September 2024 stating residents aged 65 or older represented 19.2% of South Korea’s population, reinforcing accessible hematology-service requirements across regional oncology networks. Tertiary hospitals provide early settings for protocol-led adoption and specialist education. Sector in South Korean is anticipated to record 6.7% CAGR during the assessment period, backed by prompt evidence assessment and coordinated oncology care. Prompt protocol review supports early uptake within major cancer hospitals. Shared training materials help regional centers prepare patients for referral and post-dose monitoring.
• American Cancer Society projected in January 2026 for approximately 79,320 non-Hodgkin lymphoma diagnoses across the United States during 2026, sustaining treatment demand across academic and community services. Established bispecific-antibody and cellular-therapy experience supports detailed comparison of clinical outcomes and patient access. The market in the United States is predicted to progress at 6.4% CAGR during the forecast period, helped by outpatient expansion and coverage decisions. Coverage variation may produce uneven access between academic centers and community practices. Medical-support programs reduce implementation gaps led by education and case-specific guidance.

Who are notable companies in Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market?

F. Hoffmann-La Roche Ltd. and Genentech, Inc. develop Lunsumio VELO and Polivy for relapsed or refractory LBCL treatment. AbbVie Inc. and Genmab A/S participate through subcutaneous epcoritamab development. Bristol Myers Squibb supports treatment comparison through Breyanzi cellular therapy.

Competition in subcutaneous Lunsumio VELO Polivy relapsed refractory LBCL is anticipated to center on response durability and outpatient feasibility. Hospital teams are likely to compare companies driven by treatment evidence and specialist education prior to regimen selection. Roche and Genentech are expected to receive attention led by direct Lunsumio VELO and Polivy development. AbbVie and Genmab are projected to support comparison through a subcutaneous CD20xCD3 bispecific-antibody program. Bristol Myers Squibb is estimated to retain a distinct position through approved engineered cell therapy for eligible relapsed LBCL patients.

• F. Hoffmann-La Roche Ltd. and Genentech, Inc. are expected to gain review attention based on direct Subcutaneous Lunsumio + Polivy development. Clinical teams are likely to assess fixed-duration treatment and community delivery support across complete care pathways.
• AbbVie Inc. and Genmab A/S are anticipated to compete based on epcoritamab and established subcutaneous bispecific-antibody experience. Hematology programs are projected to compare response durability and outpatient dosing procedures across eligible patient groups.
• Bristol Myers Squibb is forecast to retain specialist attention due to Breyanzi across relapsed or refractory large B-cell lymphoma treatment. Cellular-therapy referral requirements create a separate access pathway from outpatient-ready bispecific combinations.
• Company comparison is likely to reflect clinical evidence and specialist education together with dependable supply and safety support. Hospital approval is anticipated to favor treatments supported by complete protocols and regional medical assistance.

Competitive Benchmarking: Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market

Company	Portfolio Depth	Clinical Match	Service Support	Service Reach
F. Hoffmann-La Roche Ltd.	High	High	High	Global markets
Genentech, Inc.	High	High	High	United States
AbbVie Inc.	High	High	High	United States and selected global markets
Genmab A/S	High	High	Medium	United States and European markets

Source: Competitive analysis, 2026.

Key Developments in Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market

• In June 2025, Genmab announced EPCORE NHL-2 findings for subcutaneous epcoritamab combined with R-ICE among transplant-eligible relapsed or refractory DLBCL patients. Company results documented an 87% overall response rate, promoting competitive review of subcutaneous bispecific-antibody combinations across salvage treatment pathways.
• In January 2026, Genmab announced positive phase III EPCORE DLBCL-1 topline results for subcutaneous epcoritamab monotherapy in transplant-ineligible relapsed or refractory DLBCL. Company findings recorded a 0.74 progression-free-survival hazard ratio, strengthening regulatory planning for an outpatient bispecific-antibody competitor.
• In June 2026, Roche announced United States regulatory acceptance of its supplemental application for Lunsumio VELO combined with Polivy in relapsed or refractory LBCL. Review acceptance moved the combination closer to potential use following at least one prior systemic therapy.

Key Players in Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market

Direct Lunsumio and Polivy developers

• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.

Subcutaneous bispecific-antibody developers

• AbbVie Inc.
• Genmab A/S

Cellular-therapy competitor

• Bristol Myers Squibb

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market Report Scope

Coverage Field	Report Scope
Market Breakdown	Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market breakdown by therapy regimen, line of therapy, end user, route of administration, and region.
Quantitative Units	Revenue in USD Million, CAGR in %.
Market Definition	Subcutaneous Lunsumio VELO Polivy relapsed refractory LBCL coverage includes products and supporting services used directly across the defined treatment pathway
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa
Countries Covered	Germany, Japan, United Kingdom, South Korea, and United States
Key Companies Profiled	F. Hoffmann-La Roche Ltd., Genentech, Inc., AbbVie Inc., Genmab A/S, and Bristol Myers Squibb
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology using segment share and country CAGR with treatment activity, company participation, clinical evidence, and service coverage

Source: Report-scope analysis, 2026.

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, sourcing teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Source: Research methodology, 2026.

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market by Segments

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market segmented by Therapy Regimen:

• Subcutaneous Lunsumio + Polivy (VELO)
• Lunsumio Monotherapy
• Polivy Combination Therapy
• Other Bispecific Antibody Combinations

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market segmented by Line of Therapy:

• Second-Line
• Third-Line
• Fourth-Line and Later

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market segmented by End User:

• Hospitals
• Cancer Centers
• Specialty Oncology Clinics
• Academic and Research Institutes

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market segmented by Route of Administration:

• Subcutaneous
• Intravenous

Subcutaneous Lunsumio VELO Polivy Relapsed Refractory LBCL Market segmented by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• National Cancer Institute. (2025, February 26). Lymphoma SPOREs.
• ClinicalTrials.gov. (2026, May 6). A study evaluating efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin compared to rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
• Budde, L. E., Olszewski, A. J., Assouline, S., Lossos, I. S., Diefenbach, C., Kamdar, M., Ghosh, N., Modi, D., Sabry, W., Naik, S., Mehta, A., Nakhoda, S. K., Smith, S. D., Dorritie, K., Jia, T., Pham, S., Huw, L.-Y., Jing, J., Wu, H., Ead, W. S., To, I., Batlevi, C. L., Wei, M. C., & Chavez, J. C. (2024). Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B-cell lymphoma: A phase 1b/2 trial. Nature Medicine, 30(1), 229-239.
• Budde, L. E., Zhang, H., Kim, W. S., Maruyama, D., Rego, E. M., Norasetthada, L., Hong, H., Ozcan, M., Jeon, Y. W., de Farias, L. C., Fogliatto, L. M., Pavlovsky, A., Goto, H., Olszewski, A. J., Shah, N., Hu, B., Yin, S., Wu, H., To, I., Ead, W. S., Ashby, J., Janousek, M., Pham, S., Wang, J., Kwan, A., Batlevi, C. L., Wei, M. C., & Westin, J. (2025, October 2). Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory or relapsed large B-cell lymphoma: Primary results of the phase III SUNMO trial. Journal of Clinical Oncology, 43(36), 3799-3811.
• Chavez, J. C., Bastos-Oreiro, M., Diefenbach, C., Lossos, I. S., Shah, N., Assouline, S., Olszewski, A. J., Naik, S., Ghosh, N., Pham, S., Wei, M. C., Batlevi, C., To, I., Ead, W., Makadia, S., Penuel, E., Jing, J., & Budde, L. E. (2026, June 12). A randomized phase II study of subcutaneous mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory large B-cell lymphoma. American Journal of Hematology.
• Roche. (2025, September 19). CHMP recommends European Union approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma.
• Genentech, Inc. (2025, December 8). Genentech presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas.
• Genentech, Inc. (2025, December 21). FDA approves Genentech’s Lunsumio VELO for subcutaneous use in relapsed or refractory follicular lymphoma.
• Genmab A/S. (2025, September 3). Genmab announces updated results from phase 2 EPCORE NHL-6 study evaluating epcoritamab monotherapy in the outpatient setting in patients with relapsed or refractory diffuse large B-cell lymphoma.
• Eurostat. (2026, July 13). EU hospital bed count at 507 per 100,000 people.
• Statistics Bureau of Japan. (2025, April 14). Current population estimates as of October 1, 2024.
• NHS England. (2026, March 3). Cancer Services Profiles, 2025 annual update.
• Ministry of Data and Statistics. (2024, September 26). 2024 statistics on the aged.
• American Cancer Society. (2026, January 13). Key statistics for non-Hodgkin lymphoma.
• Bristol Myers Squibb Canada. (2025, January 13). CAR T cell therapy Breyanzi approved for second-line relapsed or refractory diffuse large B-cell lymphoma.
• Genmab A/S. (2025, June 15). Genmab announces epcoritamab investigational combination therapy demonstrates high response rates in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplantation.
• Genmab A/S. (2026, January 16). Genmab announces topline results for epcoritamab from phase 3 EPCORE DLBCL-1 trial in patients with relapsed or refractory diffuse large B-cell lymphoma.
• Roche. (2026, June 18). FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• What segments influence demand across therapy regimen and line of therapy with end user and route of administration?
• How do hematology teams evaluate subcutaneous Lunsumio VELO and Polivy prior to routine treatment use?
• How do country CAGRs differ across profiled healthcare systems with distinct specialist capacity and treatment access?
• What companies compete through treatment evidence and dependable regional clinical support?
• How are forecasts validated through hybrid bottom-up and top-down analysis using independent indicators and company evidence?
• What evidence do hospital committees examine prior to multi-site treatment expansion?
• How do response durability and toxicity-management requirements influence regimen selection?
• What limits return on investment for hospitals adding subcutaneous lymphoma treatment pathways?
• How do education records and specialist guidance influence hospital approval across multidisciplinary clinical teams?
• What company capabilities improve long-term clinical confidence and continuing treatment use?